^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PPAR γ agonist

    Related drugs:
    8d
    CHIG-MASH: A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus (clinicaltrials.gov)
    P2, N=300, Recruiting, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    15d
    Multi-omics integration deciphers immune-metabolic heterogeneity in colorectal cancer: a prognostic model and therapeutic strategies targeting ANGPTL4/FABP4/RBP7 (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    The constructed prognostic model and the identified potential therapeutic targets provide new strategies to address immune therapy resistance for CRC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • FABP4 (Fatty Acid Binding Protein 4) • RBP7 (Retinol Binding Protein 7)
    |
    PD-L1 expression
    |
    rosiglitazone
    16d
    Cilostazol inhibits TGF-α-induced migration of hepatocellular carcinoma cells by activating PPARγ. (PubMed, Biochem Biophys Res Commun)
    We also found that PPARγ activators, ciglitazone and pioglitazone, significantly inhibited the TGF-α-induced migration of HuH7 cells. Cilostazol and dipyridamole also inhibited the activation of AKT but not EGFR. Taken together, these results strongly suggest that cilostazol and dipyridamole inhibit TGF-α-induced HCC cell migration by suppressing the AKT pathway through PPARγ activation.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    20d
    GC-MS metabolomic profiling and PPARγ-targeted in silico approaches for identifying a potential anti-diabetic compound from traditional rice varieties. (PubMed, Front Nutr)
    Molecular docking using PyRx, followed by refined docking with the Schrödinger Glide XP module and binding free energy analysis using Schrödinger Prime MM-GBSA, identified oleic acid (PubChem ID: 445639) as the most promising compound, with a docking score of -9.451 kcal/mol and binding free energy (ΔGbind) of -108.21 kcal/mol, compared to the reference antidiabetic drug pioglitazone (PubChem ID: 4829; -8.759 kcal/mol ΔGbind = -96.81 kcal/mol)...Structural analyses, including root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), solvent-accessible surface area (SASA), hydrogen bond interactions, principal component analysis (PCA), free energy landscape (FEL), and Molecular Mechanics/Poisson-Boltzmann Surface Area (MM-PBSA) binding energy calculations analysis, indicated stable binding behavior of the PPARγ-oleic acid complex throughout the simulation. These findings suggest that oleic acid may act as a potential natural modulator of PPARγ, highlighting the therapeutic potential of traditional rice varieties as sources of antidiabetic bioactive compounds.
    Journal • Metabolomic study
    |
    PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    22d
    A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (clinicaltrials.gov)
    P3, N=1000, Active, not recruiting, Inventiva Pharma | Trial completion date: Jun 2027 --> Sep 2027 | Trial primary completion date: Jun 2027 --> Sep 2027
    Trial completion date • Trial primary completion date
    22d
    2023-509452-34-00: Testing a New Medication (Etrinabdiona) for Leg Circulation disease: A Study of Safety, Tolerability and Preliminary Efficacy (2023-509452-34-00)
    P1/2, N=30, Completed, Vivacell Biotechnology Espana S.L. | Not yet recruiting --> Completed
    Trial completion
    27d
    CT-L03-301: Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin (clinicaltrials.gov)
    P3, N=606, Completed, Celltrion | Active, not recruiting --> Completed
    Trial completion
    27d
    A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (clinicaltrials.gov)
    P3, N=1000, Active, not recruiting, Inventiva Pharma | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    29d
    Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis (clinicaltrials.gov)
    P3, N=102, Active, not recruiting, Zydus Therapeutics Inc. | Recruiting --> Active, not recruiting | N=150 --> 102
    Enrollment closed • Enrollment change
    30d
    Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes (clinicaltrials.gov)
    P=N/A, N=3550, Not yet recruiting, Chipscreen Biosciences, Ltd.
    New trial
    30d
    EPICS-IV: Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy (clinicaltrials.gov)
    P3, N=89, Not yet recruiting, Zydus Therapeutics Inc. | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date
    1m
    Evaluation of Chiglitazar Sodium With Lifestyle Intervention for Reversing Prediabetes (clinicaltrials.gov)
    P=N/A, N=472, Not yet recruiting, Second Xiangya Hospital of Central South University
    New trial